US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Onconetix Inc.

4.15

+0.540014.96%

Post-market: 4.05-0.1000-2.41%16:39 EDT

Volume:579.07K

Turnover:2.32M

Market Cap:2.17M

PE:0.00

High:4.27

Open:3.59

Low:3.52

Close:3.61

Loading ...

Overview Company News Filings

Onconetix Inc. and Ocuvex Therapeutics Announce Definitive Merger Agreement to Accelerate Ophthalmic Treatments

BRIEF-Onconetix, Inc. Announces Positive Decision By Nasdaq Hearings Panel

Onconetix Inc. Completes 1-for-85 Reverse Stock Split to Meet Nasdaq Compliance

Onconetix Inc trading halted, news pending

Onconetix Inc. Announces 1-for-85 Reverse Stock Split to Regain Nasdaq Compliance

Onconetix Inc. Conducted Special Meeting of Stockholders

Onconetix Inc. Reports 4217% Surge in Revenue for 2024, Yet Net Loss Widens by 57%

Onconetix Inc. Faces Potential Nasdaq Delisting; Hearing Scheduled for May 27, 2025

Onconetix receives additional delisting notice from Nasdaq

Onconetix Inc. Faces Nasdaq Delisting Threat Due to Delayed Financial Reports

Onconetix receives additional notice from Nasdaq

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

BRIEF-Onconetix Sets Stage For Potential Business Combination With Ocuvex Therapeutics

Onconetix, Ocuvex Therapeutics Sign Letter of Intent for Potential Merger; Shares Up Pre-Bell

MT Newswires Live

Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.

Onconetix Names Interim CFO Karina Fedasz as Interim CEO

Onconetix claims validation of prostate cancer test Proclarix in Danish cohort

BRIEF-Onconetix Says Ralph Schiess Resigns As Interim CEO And Chief Science Officer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ONCO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONCO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONCO\",,,,,undefined,":{"symbol":"ONCO","market":"US","secType":"STK","nameCN":"Onconetix Inc.","latestPrice":4.15,"timestamp":1753473600000,"preClose":3.61,"halted":0,"volume":579066,"hourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":4.15,"latestTime":"16:39 EDT","volume":6197,"amount":25136.404635500003,"timestamp":1753475998747},"delay":0,"floatShares":461258,"shares":521863,"eps":-6055.384,"marketStatus":"Post-Mkt","change":0.54,"latestTime":"07-25 16:40:27 EDT","open":3.59,"high":4.2662,"low":3.52,"amount":2319247.7533782,"amplitude":0.206704,"askPrice":4.2,"askSize":100,"bidPrice":3.96,"bidSize":3,"shortable":3,"etf":0,"ttmEps":-6055.384,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1753488000000},"marketStatusCode":4,"adr":0,"listingDate":1645160400000,"exchange":"NASDAQ","adjPreClose":3.61,"preHourTrading":{"tag":"盘前","latestPrice":3.59,"preClose":3.61,"latestTime":"09:27 EDT","volume":2698,"amount":9652.966454,"timestamp":1753450070020},"postHourTrading":{"tag":"盘后","latestPrice":4.05,"preClose":4.15,"latestTime":"16:39 EDT","volume":6197,"amount":25136.404635500003,"timestamp":1753475998747},"volumeRatio":3.163479},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONCO\",,,,,undefined,":{"symbol":"ONCO","floatShares":461258,"roa":"-8.25%","roe":"-1180.06%","lyrEps":-7433.2466,"volumeRatio":3.163479,"shares":521863,"dividePrice":0,"high":4.2662,"amplitude":0.206704,"preClose":3.61,"low":3.52,"week52Low":3.16,"pbRate":"0.54","psRate":"1.12","week52High":656.88,"institutionHeld":0,"latestPrice":4.15,"committee":-0.941748,"eps":-6055.384,"divideRate":0,"volume":579066,"delay":0,"ttmEps":-6055.384,"open":3.59,"prevYearClose":53.55,"prevWeekClose":3.44,"prevMonthClose":4.77,"prevQuarterClose":4.77,"fiveDayClose":3.44,"twentyDayClose":4.65,"sixtyDayClose":6.4685},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONCO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551128534","title":"Onconetix Inc. and Ocuvex Therapeutics Announce Definitive Merger Agreement to Accelerate Ophthalmic Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2551128534","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551128534?lang=en_us&edition=fundamental","pubTime":"2025-07-16 20:17","pubTimestamp":1752668234,"startTime":"0","endTime":"0","summary":"Onconetix, Inc.  and Ocuvex Therapeutics, Inc. have announced the execution of a definitive merger agreement, which has been approved by the boards of both companies. Under the agreement, Onconetix will acquire all outstanding equity interests of Ocuvex. Ocuvex equity holders will receive newly-issued Onconetix common stock, representing 90% of the combined company's equity. Onconetix shareholders will hold the remaining 10%. Post-merger, the Onconetix board will comprise seven directors, with five designated by Ocuvex and two by Onconetix. The transaction is expected to close in the fourth quarter of this year, subject to customary approvals. Anthony W. Amato, Chairman and CEO of Ocuvex, emphasized the benefits of accessing public capital markets to advance new treatment options. Andrew J. Oakley, Chairman of Onconetix, highlighted the value brought by Ocuvex's ophthalmic assets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. W","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDLY8F8Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","LU2095319765.USD","BK4585","ONCO","BK4588","BK4139","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","LU2210150020.SGD","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2543314677","title":"BRIEF-Onconetix, Inc. Announces Positive Decision By Nasdaq Hearings Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2543314677","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543314677?lang=en_us&edition=fundamental","pubTime":"2025-06-16 20:32","pubTimestamp":1750077161,"startTime":"0","endTime":"0","summary":"BRIEF-Onconetix, Inc. Announces Positive Decision By Nasdaq Hearings PanelJune 16 (Reuters) - Onconetix Inc ONCO.O:ONCONETIX, INC. ANNOUNCES POSITIVE DECISION BY NASDAQ HEARINGS PANELONCONETIX INC: EX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nFWN3SJ09L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2543722266","title":"Onconetix Inc. Completes 1-for-85 Reverse Stock Split to Meet Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2543722266","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543722266?lang=en_us&edition=fundamental","pubTime":"2025-06-16 20:22","pubTimestamp":1750076529,"startTime":"0","endTime":"0","summary":"Onconetix Inc.  has announced a 1-for-85 reverse stock split of its outstanding shares of common stock, effective at 12:01 a.m. Eastern Time on June 13, 2025. This move is part of the company's efforts to comply with Nasdaq's listing requirements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via GlobeNewswire  on June 16, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250616:nNDLQNPPz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","IE00B3QW5Z07.USD","BK4139","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4112","BK4585","LU2210149790.SGD","LU2095319765.USD","BK4588"],"gpt_icon":0},{"id":"2543525457","title":"Onconetix Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2543525457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543525457?lang=en_us&edition=fundamental","pubTime":"2025-06-13 07:50","pubTimestamp":1749772223,"startTime":"0","endTime":"0","summary":"19:50 EDT Onconetix (ONCO) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onconetix-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onconetix-inc-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2542535467","title":"Onconetix Inc. Announces 1-for-85 Reverse Stock Split to Regain Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2542535467","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542535467?lang=en_us&edition=fundamental","pubTime":"2025-06-11 23:30","pubTimestamp":1749655814,"startTime":"0","endTime":"0","summary":"Onconetix Inc., a biotechnology company specializing in men's health and oncology, has announced a 1-for-85 reverse stock split effective June 13, 2025. This move, approved at the company's recent special stockholder meeting, will reduce the number of outstanding shares from approximately 44.4 million to 521,863. The company aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Onconetix will continue trading under the symbol \"ONCO\" with a new CUSIP number.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via GlobeNewswire  on June 11, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL4fMGCP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","BK4112","BK4588","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK4139","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","ONCO","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2541005935","title":"Onconetix Inc. Conducted Special Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2541005935","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541005935?lang=en_us&edition=fundamental","pubTime":"2025-06-06 04:13","pubTimestamp":1749154411,"startTime":"0","endTime":"0","summary":"On May 30, 2025, Onconetix Inc. held its 2025 special meeting of stockholders. During the meeting, two key proposals were voted on. The first proposal was to approve and adopt an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split of the company's outstanding common stock at a ratio to be determined by the Board. This proposal was approved. The second proposal was to approve the adjournment of the Special Meeting if necessary to solicit additional proxies for the Reverse Stock Split Proposal. This proposal was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL2sXnZx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ONCO"],"gpt_icon":0},{"id":"2540760384","title":"Onconetix Inc. Reports 4217% Surge in Revenue for 2024, Yet Net Loss Widens by 57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540760384","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540760384?lang=en_us&edition=fundamental","pubTime":"2025-06-02 19:42","pubTimestamp":1748864540,"startTime":"0","endTime":"0","summary":"Onconetix Inc. has released its financial results for the fiscal year ending December 31, 2024. The company reported a significant increase in revenue, reaching $2.52 million compared to $58,465 in the previous year, marking a 4217.3% surge. Despite this revenue growth, the company experienced a wider net loss of $58.69 million, compared to a net loss of $37.41 million in 2023, representing a 56.9% increase in losses. The increase in revenue was coupled with an increase in the cost of revenue, which rose to $1.47 million from $1.19 million, a 23.9% increase. As a result, the gross profit turned positive, with a gain of $1.06 million, compared to a gross loss of $1.13 million in the previous year, showing a significant improvement of 193.6%. Operating expenses saw a decrease, with selling, general, and administrative expenses dropping by 24.0% to $11.23 million from $14.77 million. Research and development expenses also saw a substantial decline of 92.1%, down to $154,359 from $1.95 mil","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL90l7Pz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Onconetix Inc. Reports 4217% Surge in Revenue for 2024, Yet Net Loss Widens by 57%","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO"],"gpt_icon":0},{"id":"2537992708","title":"Onconetix Inc. Faces Potential Nasdaq Delisting; Hearing Scheduled for May 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2537992708","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537992708?lang=en_us&edition=fundamental","pubTime":"2025-05-23 05:11","pubTimestamp":1747948296,"startTime":"0","endTime":"0","summary":"Onconetix Inc. announced it has received a delisting notice from Nasdaq due to its failure to file its Quarterly Report for the period ending March 31, 2025. Additionally, the company is not in compliance with the minimum bid price requirement, which could lead to its delisting. A hearing before the Nasdaq Hearings Panel is scheduled for May 27, 2025, which will determine the future of Onconetix's listing status. In the meantime, the company intends to file its pending reports promptly to regain compliance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDLN74Dr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2537927220","title":"Onconetix receives additional delisting notice from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2537927220","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537927220?lang=en_us&edition=fundamental","pubTime":"2025-05-23 05:00","pubTimestamp":1747947617,"startTime":"0","endTime":"0","summary":"Onconetix (ONCO) received a staff delisting letter from Nasdaq on May 20 indicating that the company’s failure to file its Quarterly Report Q for t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onconetix-receives-additional-delisting-notice-from-nasdaq-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onconetix-receives-additional-delisting-notice-from-nasdaq-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B64PRP62.GBP","ONCO","LU2210149790.SGD","TSYW.SI","USAW.SI","IE00BGHQF748.EUR","BK4112","BK4585","LU2095319765.USD","QLD","NDAQ","NVIW.SI",".IXIC","QID","TQQQ","NQmain","LU2210150020.SGD","BK4139","PSQ","BK4588","MNQmain","USJW.SI","IE00BKPKM429.USD","SQQQ","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2537927623","title":"Onconetix Inc. Faces Nasdaq Delisting Threat Due to Delayed Financial Reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2537927623","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537927623?lang=en_us&edition=fundamental","pubTime":"2025-05-23 04:50","pubTimestamp":1747947009,"startTime":"0","endTime":"0","summary":"Onconetix Inc.  has announced the receipt of a delisting notice from Nasdaq due to the company's failure to file its Quarterly Report on Form 10-Q for the period ending March 31, 2025, and its Annual Report on Form 10-K for the fiscal year ending December 31, 2024. This non-compliance with Nasdaq's listing requirements has prompted a hearing scheduled for May 27, 2025, to address the issue and consider the company's request for a stay on the suspension of its securities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onconetix Inc. published the original content used to generate this news brief via GlobeNewswire  on May 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250522:nNDL5MpyYH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4588","NDAQ","BK4585","IE00BKPKM429.USD","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4112","BK4139"],"gpt_icon":0},{"id":"2532090531","title":"Onconetix receives additional notice from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2532090531","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532090531?lang=en_us&edition=fundamental","pubTime":"2025-05-01 06:20","pubTimestamp":1746051621,"startTime":"0","endTime":"0","summary":"Onconetix (ONCO) announced that it received a Staff delisting letter from The Nasdaq Capital Market on April 24, 2025 indicating that the company’s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/onconetix-receives-additional-notice-from-nasdaq?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/onconetix-receives-additional-notice-from-nasdaq?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVIW.SI","TSYW.SI","USJW.SI","BK4112","SQQQ","NDAQ","NQmain","IE00BGHQF748.EUR","PSQ","TQQQ","LU2210149790.SGD","BK4585","MNQmain","QID","BK4139","IE00BKPKM429.USD","USAW.SI","QLD","BK4588","IE00B3QW5Z07.USD",".IXIC","LU2210150020.SGD","ONCO","IE00B64PRP62.GBP","LU2095319765.USD"],"gpt_icon":0},{"id":"2532609083","title":"Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq","url":"https://stock-news.laohu8.com/highlight/detail?id=2532609083","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532609083?lang=en_us&edition=fundamental","pubTime":"2025-05-01 06:13","pubTimestamp":1746051180,"startTime":"0","endTime":"0","summary":"Cincinnati, OH, April 30, 2025  -- Onconetix, Inc.   announced that it received a Staff delisting letter from The Nasdaq Capital Market  on April 24, 2025 indicating that the Company’s failure to file its Annual Report on Form 10-K for the fiscal year ended December 30, 2024 is in violation of Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250 .This announcement is made in compliance with Nasdaq Listing Rule 5810, which requires prompt disclosure of receipt of a deficiency notification.Onconetix is a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for men’s health and oncology. Through our acquisition of Proteomedix, we own Proclarix, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union  under the In Vitro Diagnostic Regulation . We also own ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalaf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onconetix-inc-announces-receipt-additional-221300557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B64PRP62.GBP","BK4139","SQQQ","NDAQ","LU2210150020.SGD","BK4112","TQQQ","PSQ","MNQmain","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","TSYW.SI",".IXIC","QLD","USAW.SI","USJW.SI","BK4585","NQmain","IE00B3QW5Z07.USD","BK4588","NVIW.SI","ONCO","QID","LU2095319765.USD"],"gpt_icon":1},{"id":"2525890631","title":"BRIEF-Onconetix Sets Stage For Potential Business Combination With Ocuvex Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2525890631","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525890631?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:25","pubTimestamp":1744118718,"startTime":"0","endTime":"0","summary":"BRIEF-Onconetix Sets Stage For Potential Business Combination With Ocuvex TherapeuticsApril 8 (Reuters) - Onconetix and Ocuvex Therapeutics:ONCONETIX SIGNS LETTER OF INTENT FOR POTENTIAL BUSINESS COMB","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nFWN3QM0U0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2525977538","title":"Onconetix, Ocuvex Therapeutics Sign Letter of Intent for Potential Merger; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2525977538","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525977538?lang=en_us&edition=fundamental","pubTime":"2025-04-08 21:14","pubTimestamp":1744118096,"startTime":"0","endTime":"0","summary":"Onconetix  and Ocuvex Therapeutics said Tuesday they have signed a non-binding letter of intent for a potential merger.The companies said that as part of the potential deal, Onconetix is expected to acquire Ocuvex in exchange for newly issued Onconetix shares, with Ocuvex stockholders holding about a 90% stake in Onconetix.No specific financial terms were provided. The companies said they will continue talks for a definite agreement but said there are no guarantees that a definite deal will be reached.Shares of Onconetix were 82% higher in recent Tuesday premarket activity.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ONCO","LENZ","BK4007"],"gpt_icon":0},{"id":"2525194894","title":"Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525194894","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525194894?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115400,"startTime":"0","endTime":"0","summary":"CINCINNATI, April 08, 2025  -- Onconetix, Inc.    and Ocuvex Therapeutics, Inc. , a privately held biopharmaceutical company focused on the development and commercialization of ophthalmic therapeutic candidates to address highly prevalent diseases in need of new treatment options, today announced that they have signed a Non-Binding Letter of Intent contemplating a potential business combination transaction with Ocuvex.Andrew J. Oakley, Chairman of the Board of Onconetix, stated, “We are excited about the opportunity to combine forces with Ocuvex, whose pipeline of commercial and late clinical stage ophthalmic assets will immediately expand our reach beyond oncology , enhancing shareholder value.”","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onconetix-signs-letter-intent-potential-123000397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","BK4007","ONCO"],"gpt_icon":0},{"id":"2524217649","title":"Onconetix Names Interim CFO Karina Fedasz as Interim CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2524217649","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524217649?lang=en_us&edition=fundamental","pubTime":"2025-04-04 06:34","pubTimestamp":1743719640,"startTime":"0","endTime":"0","summary":"Onconetix on Thursday said it named its interim Chief Financial Officer, Karina Fedasz, as interim Chief Executive Officer, effective immediately.Also on Thursday, the biotechnology company said James Sapirstein resigned as executive chairman and as a member of the board.Fedasz has helped companies raise capital, model and forecast business, manage cash flow and conduct mergers and acquisitions for more than two decades, Onconetix said. She has been interim CFO of Onconetix since June 2024. Before that, she worked with various clients, including a not-for-profit and an early-stage artificial intelligence and data-driven health and wellness tracker.Prior to that, Fedasz was head of business development for Evofem Biosciences, and also served in various positions of increasing responsibility, including CFO, at IDW Media Holdings, Onconetix said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4139"],"gpt_icon":0},{"id":"2522079374","title":"Onconetix claims validation of prostate cancer test Proclarix in Danish cohort","url":"https://stock-news.laohu8.com/highlight/detail?id=2522079374","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522079374?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:50","pubTimestamp":1742907044,"startTime":"0","endTime":"0","summary":"Discover stocks' market position with detailed  competitor analyses.Read More on ONCO:Questions or Comments about the article?Biotech Alert: Searches spiking for these stocks today. Onconetix to Present Proclarix at EAU Congress 2025. Onconetix announces new clinical data for Proclarix to be presented at EAU","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/onconetix-claims-validation-prostate-cancer-125044227.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/onconetix-claims-validation-prostate-cancer-125044227.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4022","BK4232","R","BK4139","ONCO"],"gpt_icon":0},{"id":"2516300915","title":"BRIEF-Onconetix Says Ralph Schiess Resigns As Interim CEO And Chief Science Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2516300915","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516300915?lang=en_us&edition=fundamental","pubTime":"2025-03-01 06:35","pubTimestamp":1740782158,"startTime":"0","endTime":"0","summary":"BRIEF-Onconetix Says Ralph Schiess Resigns As Interim CEO And Chief Science OfficerFeb 28  - Onconetix Inc ONCO.O:ONCONETIX INC - ON FEB 24 RALPH SCHIESS RESIGNS AS INTERIM CEO AND CHIEF SCIENCE OFFICERONCONETIX INC - APPOINTS JAMES SAPIRSTEIN AS EXECUTIVE CHAIRMANONCONETIX INC: APPROVED AN INCREASE TO BOARD'S SIZE FROM FIVE TO SIX MEMBERSSource text: [ID:n0001213900-25-018867]Further company coverage: ONCO.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ1U5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONCO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONCO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-06-13","symbol":"ONCO","defaultRemindTime":1749821400000,"type":"split","dateTimestamp":1749787200000,"forFactor":85,"toFactor":1,"ratio":85},{"market":"US","date":"2025-06-12","symbol":"ONCO","fiscalQuarterEnding":"2025/03","expectedEps":0,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1749700800000,"reportTimeType":"post","actualEps":0.25},{"market":"US","date":"2024-09-24","symbol":"ONCO","defaultRemindTime":1727184600000,"type":"split","dateTimestamp":1727150400000,"forFactor":40,"toFactor":1,"ratio":40},{"market":"US","date":"2024-05-20","symbol":"ONCO","fiscalQuarterEnding":"2024/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1716177600000,"reportTimeType":"post","actualEps":-0.16},{"date":"2024-04-11","symbol":"ONCO","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1712865600000,"name":null,"time":"Post Market","dateTimestamp":1712808000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONCO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONCO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONCO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONCO","date":"2025-07-24","current":-0.034779,"percent":0.847594,"low":-0.968106,"twenty":-0.194728,"median":-0.080109,"eighty":-0.040628,"high":-0.008728,"avg":-0.142623,"sd":0.182702,"marketCap":1951767},"quantilePoints":[{"date":"2023-12-29","current":-0.201955,"twenty":-0.205826,"median":-0.201955,"eighty":-0.193917,"marketCap":3691085},{"date":"2024-01-05","current":-0.194459,"twenty":-0.201955,"median":-0.195264,"eighty":-0.193719,"marketCap":3554077},{"date":"2024-01-12","current":-0.190736,"twenty":-0.197125,"median":-0.193719,"eighty":-0.190736,"marketCap":3486030},{"date":"2024-01-19","current":-0.173836,"twenty":-0.19628,"median":-0.192899,"eighty":-0.180094,"marketCap":3177158},{"date":"2024-01-26","current":-0.342039,"twenty":-0.19628,"median":-0.189647,"eighty":-0.1728,"marketCap":6251352},{"date":"2024-02-02","current":-0.174037,"twenty":-0.202407,"median":-0.192246,"eighty":-0.173635,"marketCap":3180835},{"date":"2024-02-09","current":-0.164782,"twenty":-0.198091,"median":-0.186679,"eighty":-0.170436,"marketCap":3011681},{"date":"2024-02-16","current":-0.205696,"twenty":-0.198091,"median":-0.184801,"eighty":-0.168042,"marketCap":3759458},{"date":"2024-02-23","current":-0.206429,"twenty":-0.205989,"median":-0.188558,"eighty":-0.169852,"marketCap":3772853},{"date":"2024-03-01","current":-0.208872,"twenty":-0.20842,"median":-0.192572,"eighty":-0.172015,"marketCap":3817502},{"date":"2024-03-08","current":-0.22182,"twenty":-0.213025,"median":-0.193719,"eighty":-0.17277,"marketCap":4054143},{"date":"2024-03-15","current":-0.201665,"twenty":-0.217422,"median":-0.196597,"eighty":-0.172951,"marketCap":3685787},{"date":"2024-03-22","current":-0.203986,"twenty":-0.21515,"median":-0.197125,"eighty":-0.173514,"marketCap":3728204},{"date":"2024-03-28","current":-0.2002,"twenty":-0.212952,"median":-0.198734,"eighty":-0.173916,"marketCap":3658998},{"date":"2024-04-05","current":-0.204475,"twenty":-0.211193,"median":-0.198734,"eighty":-0.174238,"marketCap":3737134},{"date":"2024-04-12","current":-0.093154,"twenty":-0.209947,"median":-0.197125,"eighty":-0.174238,"marketCap":3484866},{"date":"2024-04-19","current":-0.079022,"twenty":-0.209385,"median":-0.195935,"eighty":-0.172739,"marketCap":2956187},{"date":"2024-04-26","current":-0.07186,"twenty":-0.2087,"median":-0.194214,"eighty":-0.166713,"marketCap":2688255},{"date":"2024-05-03","current":-0.067443,"twenty":-0.208428,"median":-0.193586,"eighty":-0.15949,"marketCap":2523030},{"date":"2024-05-10","current":-0.066787,"twenty":-0.208202,"median":-0.192246,"eighty":-0.083892,"marketCap":2498469},{"date":"2024-05-17","current":-0.084155,"twenty":-0.207504,"median":-0.190061,"eighty":-0.075083,"marketCap":3148205},{"date":"2024-05-24","current":-0.069112,"twenty":-0.206722,"median":-0.188558,"eighty":-0.074211,"marketCap":3157136},{"date":"2024-05-31","current":-0.116278,"twenty":-0.206282,"median":-0.18621,"eighty":-0.07464,"marketCap":5311760},{"date":"2024-06-07","current":-0.08705,"twenty":-0.205452,"median":-0.178162,"eighty":-0.074985,"marketCap":3976563},{"date":"2024-06-14","current":-0.070578,"twenty":-0.204475,"median":-0.174289,"eighty":-0.074605,"marketCap":3224120},{"date":"2024-06-21","current":-0.075759,"twenty":-0.204269,"median":-0.173433,"eighty":-0.074474,"marketCap":3460793},{"date":"2024-06-28","current":-0.100148,"twenty":-0.204171,"median":-0.17293,"eighty":-0.07408,"marketCap":4574945},{"date":"2024-07-05","current":-0.078056,"twenty":-0.203986,"median":-0.171849,"eighty":-0.074605,"marketCap":3565733},{"date":"2024-07-12","current":-0.070578,"twenty":-0.203986,"median":-0.1678,"eighty":-0.07371,"marketCap":3224120},{"date":"2024-07-15","current":-0.074977,"twenty":-0.203742,"median":-0.166895,"eighty":-0.073758,"marketCap":3425069},{"date":"2024-08-02","current":-0.097024,"twenty":-0.203498,"median":-0.165989,"eighty":-0.073806,"marketCap":4432207},{"date":"2024-08-09","current":-0.087113,"twenty":-0.202765,"median":-0.164732,"eighty":-0.074211,"marketCap":3979455},{"date":"2024-08-16","current":-0.091286,"twenty":-0.202441,"median":-0.148887,"eighty":-0.074675,"marketCap":4170088},{"date":"2024-08-23","current":-0.103936,"twenty":-0.201937,"median":-0.114182,"eighty":-0.074801,"marketCap":4747943},{"date":"2024-08-30","current":-0.075134,"twenty":-0.201812,"median":-0.103936,"eighty":-0.074889,"marketCap":3991369},{"date":"2024-09-06","current":-0.071275,"twenty":-0.201372,"median":-0.101719,"eighty":-0.07464,"marketCap":3786324},{"date":"2024-09-13","current":-0.074303,"twenty":-0.199931,"median":-0.100613,"eighty":-0.073472,"marketCap":3947190},{"date":"2024-09-20","current":-0.06477,"twenty":-0.198832,"median":-0.097806,"eighty":-0.072904,"marketCap":3440758},{"date":"2024-09-27","current":-0.047041,"twenty":-0.198734,"median":-0.097089,"eighty":-0.072123,"marketCap":2498940},{"date":"2024-10-04","current":-0.702586,"twenty":-0.201861,"median":-0.097806,"eighty":-0.072322,"marketCap":37323522},{"date":"2024-10-11","current":-0.804153,"twenty":-0.203742,"median":-0.100613,"eighty":-0.072761,"marketCap":42719049},{"date":"2024-10-18","current":-0.880664,"twenty":-0.205452,"median":-0.101719,"eighty":-0.072874,"marketCap":46783580},{"date":"2024-10-25","current":-0.626146,"twenty":-0.208304,"median":-0.106675,"eighty":-0.072904,"marketCap":33262793},{"date":"2024-10-31","current":-0.46218,"twenty":-0.209727,"median":-0.114182,"eighty":-0.073022,"marketCap":24552412},{"date":"2024-11-08","current":-0.379425,"twenty":-0.217422,"median":-0.148887,"eighty":-0.073022,"marketCap":20156203},{"date":"2024-11-15","current":-0.254511,"twenty":-0.219865,"median":-0.164732,"eighty":-0.073315,"marketCap":13520416},{"date":"2024-11-22","current":-0.17644,"twenty":-0.219499,"median":-0.165989,"eighty":-0.073412,"marketCap":9373049},{"date":"2024-11-29","current":-0.107738,"twenty":-0.218815,"median":-0.165889,"eighty":-0.07365,"marketCap":5723366},{"date":"2024-12-06","current":-0.098369,"twenty":-0.217666,"median":-0.160355,"eighty":-0.073901,"marketCap":5225682},{"date":"2024-12-13","current":-0.075065,"twenty":-0.217422,"median":-0.144138,"eighty":-0.074232,"marketCap":3873640},{"date":"2024-12-20","current":-0.057866,"twenty":-0.214393,"median":-0.114182,"eighty":-0.073393,"marketCap":2986104},{"date":"2024-12-27","current":-0.056259,"twenty":-0.21261,"median":-0.110145,"eighty":-0.072963,"marketCap":2903156},{"date":"2025-01-03","current":-0.104658,"twenty":-0.211193,"median":-0.107738,"eighty":-0.072874,"marketCap":5400701},{"date":"2025-01-10","current":-0.087844,"twenty":-0.210021,"median":-0.107738,"eighty":-0.072904,"marketCap":4533072},{"date":"2025-01-17","current":-0.082411,"twenty":-0.209556,"median":-0.104481,"eighty":-0.073022,"marketCap":4252710},{"date":"2025-01-24","current":-0.077155,"twenty":-0.208872,"median":-0.103034,"eighty":-0.073022,"marketCap":3981472},{"date":"2025-01-31","current":-0.090802,"twenty":-0.208442,"median":-0.10198,"eighty":-0.073315,"marketCap":4685695},{"date":"2025-02-07","current":-0.105075,"twenty":-0.208406,"median":-0.10224,"eighty":-0.073412,"marketCap":5422267},{"date":"2025-02-14","current":-0.087185,"twenty":-0.207895,"median":-0.101296,"eighty":-0.07371,"marketCap":4499063},{"date":"2025-02-21","current":-0.067511,"twenty":-0.207113,"median":-0.100929,"eighty":-0.073393,"marketCap":3483788},{"date":"2025-02-28","current":-0.049315,"twenty":-0.206527,"median":-0.100148,"eighty":-0.072875,"marketCap":2544824},{"date":"2025-03-07","current":-0.036777,"twenty":-0.205843,"median":-0.098528,"eighty":-0.072195,"marketCap":1897835},{"date":"2025-03-14","current":-0.020864,"twenty":-0.204719,"median":-0.098369,"eighty":-0.071225,"marketCap":1076656},{"date":"2025-03-21","current":-0.020944,"twenty":-0.204269,"median":-0.097978,"eighty":-0.070572,"marketCap":1080803},{"date":"2025-03-28","current":-0.017312,"twenty":-0.204032,"median":-0.097741,"eighty":-0.069818,"marketCap":893342},{"date":"2025-04-04","current":-0.0122,"twenty":-0.203986,"median":-0.097063,"eighty":-0.069089,"marketCap":629570},{"date":"2025-04-11","current":-0.009323,"twenty":-0.203009,"median":-0.096444,"eighty":-0.068134,"marketCap":481094},{"date":"2025-04-17","current":-0.00958,"twenty":-0.202765,"median":-0.095559,"eighty":-0.067511,"marketCap":494366},{"date":"2025-04-25","current":-0.011091,"twenty":-0.202279,"median":-0.093131,"eighty":-0.066512,"marketCap":572336},{"date":"2025-05-02","current":-0.012554,"twenty":-0.201928,"median":-0.092586,"eighty":-0.065058,"marketCap":647818},{"date":"2025-05-09","current":-0.011702,"twenty":-0.201763,"median":-0.090913,"eighty":-0.063884,"marketCap":603856},{"date":"2025-05-16","current":-0.011991,"twenty":-0.200786,"median":-0.088907,"eighty":-0.05784,"marketCap":618787},{"date":"2025-05-23","current":-0.023761,"twenty":-0.199394,"median":-0.088096,"eighty":-0.054651,"marketCap":1226160},{"date":"2025-05-30","current":-0.068768,"twenty":-0.198807,"median":-0.087659,"eighty":-0.054651,"marketCap":3548673},{"date":"2025-06-06","current":-0.052528,"twenty":-0.198734,"median":-0.087113,"eighty":-0.054651,"marketCap":3082910},{"date":"2025-06-13","current":-0.058572,"twenty":-0.19856,"median":-0.086807,"eighty":-0.054651,"marketCap":3286955},{"date":"2025-06-20","current":-0.037197,"twenty":-0.198065,"median":-0.086363,"eighty":-0.052105,"marketCap":2087452},{"date":"2025-06-27","current":-0.043242,"twenty":-0.196958,"median":-0.084244,"eighty":-0.047082,"marketCap":2426662},{"date":"2025-07-03","current":-0.043242,"twenty":-0.196291,"median":-0.084155,"eighty":-0.044358,"marketCap":2426662},{"date":"2025-07-11","current":-0.040638,"twenty":-0.196069,"median":-0.082194,"eighty":-0.043707,"marketCap":2280541},{"date":"2025-07-18","current":-0.033199,"twenty":-0.195802,"median":-0.081722,"eighty":-0.043242,"marketCap":1863050},{"date":"2025-07-24","current":-0.034779,"twenty":-0.194728,"median":-0.080109,"eighty":-0.040628,"marketCap":1951767}],"updateTime":1753450481463}}}